SWITCHED ON
The daily technology series nobody asked for but everyone needed
Spare Parts: Lab-Grown Organs and the 3D Bioprinting Revolution
Around 100,000 people are waiting for an organ transplant in the United States alone. The question of whether technology can fix that is no longer purely hypothetical.
Every seventeen minutes, someone in the United States is added to the organ transplant waiting list. Every day, approximately twenty people on that list die waiting. These are not statistics that require a technology that works perfectly. They require a technology that works better than nothing. The bar, in other words, is achievable.
Yesterday we tackled anti-aging technology — the twelve hallmarks of aging, the rapamycin question, the billionaire biohacker circus, and the deeply underexplored civilisational consequences of meaningfully extending human lifespan. Today we are staying in the domain of biology but moving to a problem with a more immediate and less philosophically contested humanitarian dimension. People are dying for want of organs. The waiting list for a kidney transplant in the United States currently runs to years. The waiting list for a heart is measured in months, during which the patient's survival is not guaranteed. Lab-grown organs and 3D bioprinting represent the most plausible technological route to solving this problem. The question is how far the technology has actually come, and how far it still needs to go.
The honest answer, as is so often the case in this series, is: further than most people realise, and not as far as the press releases suggest. Let's start from the beginning.
01 — The Scope of the Problem
Organ failure is one of the leading causes of death globally. The kidney is the most commonly transplanted organ — roughly 100,000 people in the United States are on the waiting list at any given time, with average wait times of three to five years. During that time, patients undergo dialysis, a life-sustaining but physically gruelling and enormously expensive treatment that imposes enormous burdens on patients and healthcare systems. Approximately 13 people die every day in the US alone while waiting for a kidney.
Hearts, livers, lungs, and pancreases face similar dynamics — demand that consistently and substantially exceeds supply. The supply constraint is structural: organs for transplant come primarily from deceased donors, a pool that is finite and that requires a precise combination of timing, compatibility, and logistics that fails more often than it succeeds. Living donor programs for kidneys and partial liver transplants have expanded the supply somewhat but cannot close the gap.
The immune system adds another layer of complexity. Even when a donor organ is available and transplanted successfully, the recipient's immune system recognises it as foreign and attempts to destroy it. Immunosuppressive drugs manage this response but must be taken for life, carry significant side effects, and leave patients chronically vulnerable to infection. An organ grown from the patient's own cells would, in principle, sidestep the rejection problem entirely. This is the central promise of regenerative medicine.
02 — What Has Actually Been Transplanted
The field has genuine achievements, and they deserve to be stated clearly before the caveats arrive.
Skin grafts grown from a patient's own cells have been in clinical use for decades. This is the most mature application of tissue engineering and the proof of concept that the broader field rests on. If you can grow skin, the reasoning goes, you can eventually grow anything. The reasoning is correct in principle. The execution becomes dramatically more complex as organ complexity increases.
Tissue-engineered tracheas — windpipes — were transplanted into patients beginning around 2008, using a donor trachea stripped of its cells and repopulated with the patient's own stem cells. The results were initially reported as successes. Subsequent follow-up revealed serious complications and several patient deaths. The lead researcher, Paolo Macchiarini, was later found to have committed research misconduct and misrepresented patient outcomes. The case became one of the most significant scandals in modern surgical history and a sobering reminder that early results in this field require rigorous scrutiny.
Bladders grown from patients' own cells were successfully transplanted by Anthony Atala's team at Wake Forest in a series of patients beginning in the late 1990s, with results published in 2006. These remain among the clearest demonstrations that a hollow organ can be engineered from autologous cells and function in the human body. The bladder is, structurally, one of the simpler organs — a relatively uniform tissue without the vascular complexity of organs like the kidney or heart.
The fundamental challenge in organ engineering is not growing cells. It is growing the intricate vascular network that keeps them alive — the capillaries and vessels that deliver oxygen and nutrients to every cell in a thick, solid tissue.
In 2022, surgeons at NYU Langone successfully transplanted a genetically modified pig kidney into a human patient — the kidney was attached externally and functioned for 54 hours before the experiment was concluded. In 2023 and 2024, further xenotransplantation experiments — using pig organs modified with human genes to reduce rejection — were conducted, including a pig heart transplant into a living patient who survived 60 days before dying of what was likely a viral infection carried by the pig organ. These results are simultaneously remarkable as proof of concept and sobering as demonstrations of how far the technology remains from routine clinical use.
03 — The Vascularisation Problem
Every cell in a solid organ needs to be within roughly 200 micrometres of a blood vessel to receive adequate oxygen. The human kidney contains approximately one million nephrons, each served by an intricate capillary network. The liver processes blood through a dual vascular system of extraordinary complexity. The heart is a pump made of muscle that must be continuously supplied with blood even as it pumps blood to everything else.
Growing cells is relatively straightforward. Growing the vascular architecture that keeps them alive in a thick, solid tissue is the central unsolved problem of organ engineering. Current approaches include decellularisation — taking a donor organ, stripping it of its cells using detergents to leave only the extracellular matrix scaffold, then repopulating that scaffold with the patient's own cells. The scaffold preserves the vascular channels of the original organ, providing a template for the new vasculature to follow. The approach has shown promise in animal models and is the basis for several ongoing research programs for kidneys and hearts.
3D bioprinting offers another route. Rather than using a biological scaffold, bioprinting attempts to construct organ tissue layer by layer, depositing cells and supporting materials in precise spatial arrangements according to a digital design. The technology has advanced considerably — researchers have printed functional kidney tissue, cardiac tissue that beats spontaneously, and liver organoids that perform metabolic functions. Printing a complete, transplantable organ with full vascular integration remains beyond current capability, but the trajectory is encouraging.
04 — Organoids and What They're Actually For
Organoids — miniature, self-organising structures grown from stem cells that partially replicate the architecture and function of real organs — represent a genuinely transformative development in biological research, even if their role in transplantation medicine is more limited than the word "organ" in their name might suggest.
Researchers have developed organoids that replicate aspects of the kidney, liver, intestine, brain, lung, and numerous other tissues. These structures are not transplantable organs. They are typically a few millimetres in size, lack vasculature, and replicate only some of the functional properties of the tissue they model. What they are is an extraordinarily powerful research tool. Drug testing on organoids derived from a patient's own cells can predict that patient's response to treatment. Cancer organoids grown from tumour biopsies can be used to screen which chemotherapy regimens will be most effective for a specific patient's specific cancer. Brain organoids are being used to study neurodevelopmental conditions in ways that were previously impossible without access to living human brain tissue.
The organoid revolution is already changing pharmaceutical development and personalised medicine in ways that will have broad clinical impact over the coming decade. This impact is real and significant even though it is categorically different from the transplantable organ promise that the word "organoid" can accidentally imply.
05 — The Realistic Timeline
Tissue-engineered skin, cartilage, and simple hollow structures are clinically available now, in various forms, in various healthcare systems. These represent the current frontier of what can be reliably delivered.
Bioprinted or engineered tissues for drug testing and research applications are a near-term reality — this is happening in laboratories and is beginning to enter pharmaceutical development pipelines. The FDA has been actively engaging with the question of how to regulate organ-on-a-chip and organoid technologies as alternatives to animal testing, and has signalled openness to their use in drug development contexts.
Xenotransplantation — modified pig organs — is the most likely near-term route to addressing the organ shortage for hearts, kidneys, and livers, not because it is the most elegant solution but because the biology is further along than fully engineered alternatives. The challenges of viral contamination, immune rejection, and physiological compatibility are serious but being actively addressed by multiple research groups with significant funding. A world in which pig kidney xenotransplantation is a clinical option for some patients is probably five to fifteen years away.
Fully engineered, vascularised, transplantable solid organs grown from a patient's own cells — the full promise of the field — is a longer horizon. The vascularisation problem does not have a clear solution that is close to clinical application. The honest estimate from researchers working in the field is that this is a twenty-to-thirty-year project, not a five-year one. This does not diminish the importance of the work. It contextualises what the field can deliver and when.
The organ transplant waiting list is a solvable problem. The solution will not arrive all at once, in a single breakthrough. It will arrive incrementally, through xenotransplantation, then engineered tissues, then eventually fully personalised organs. The question is whether we are patient enough to fund the journey.
Tomorrow we are leaving the body entirely and heading into orbit. Space exploration technology: the new commercial space race, what reusable rockets have actually changed about the economics of getting to orbit, what Mars colonisation realistically requires versus what its advocates claim, and the question that tends to get lost in the excitement — whether fixing the planet we have might deserve at least comparable urgency to escaping it. See you then.
Switched On is a daily technology series covering AI, social media, data privacy, and the digital forces reshaping modern life — with no corporate spin, no false comfort, and absolutely no mercy for buzzwords.
